Article and Video CATEGORIES
What is the role for the neuroprotective agent memantine in patients receiving whole brain radiation therapy for brain metastases? Dr. Vivek Mehta reviews current practices to minimize risk of cognitive problems.
Please feel free to offer comments and raise questions in our Discussion Forums.
I see number of patients that are going to need whole brain radiation for multiple brain metastasis in the brain, and one of the questions that has come up recently is, “is there anything out there we can do to reduce the cognitive impairment that’s associated with whole brain radiation?”
Well, just a short while ago, we learned some really interesting, but preliminary, results on using a medicine called memantine. It’s actually a medicine that’s often used in Alzheimer's disease, but it was done in a study where patients who were receiving whole brain radiation either got this medication, or didn’t get this medication. The results of the study suggest that there may be a benefit in terms of preventing the onset of cognitive impairment if you get this medicine.
Now, this is one of the very first studies, and it’s a relatively small study — it probably needs to be duplicated with a larger number of patients, it probably needs to be done in more stringent fashion, to really see and tease out whether this really works. I’ll tell you that, from a radiation oncology community, there’s a fair bit of excitement about this, because we want to do anything we can to potentially reduce this particular complication, because, in the patients that get this disease and survive for a long period of time, we want to keep their mental status as high as possible.
In my clinic, when I see patients that bring this up, we often try to get this medication. One of the challenges that we have encountered is that insurance companies are not authorizing this for payment in this particular indication, and a medication, if you are buying it on your own, is awfully expensive.
So, we have not had as much success as we’d like, or the clinical experience in seeing patients truly benefit from this. It would be nice to see more studies, more data, and then convince the payers that this actually works, and that this should be moving into the standard of care. But I don’t think, today, that it’s something that we routinely offer to our patients because of these impediments.
Please feel free to offer comments and raise questions in our
Next Previous linkPrevious PostNext Post
Hi Caregiver and welcome to Grace. I'm sorry that you need to be here and hope we can help. Osimertinib has better efficacy than gefitinib (including OS and reaching the brain)...
Hi Bob, Welcome to Grace. I'm sorry about your sil. Unfortunately, cancer becomes resistant to TKIs like tagrisso. Sometimes all of the cancer becomes resistant at once and sometimes just parts...